Greg's Story – Savings from Biosimilar Medicines | Association for Accessible Medicines
AAM All Access Podcast - AAM CEO Dan Leonard convenes industry and policy experts to explore why the Inflation Reduction Act (f/k/a Build Back Better) reduces generic and biosimilar competition.

Greg's Story – Savings from Biosimilar Medicines

Steroids were not controlling Greg’s ulcerative colitis, so his gastroenterologist put him on a biologic medication. After a while, his insurance plan recommended switching to a biosimilar—a safe, effective alternative to a brand-name biologic. “My doctor was on board,” recalls Greg, a weight lifter and pizza fanatic. “I trust my doctor, so I switched to the biosimilar and it’s been smooth sailing ever since.”

Savings from biosimilars for patients like Greg totaled $8 billion in 2020 and are projected to save $133 billion over the next five years.

View Patient Stories

AAM Voices of Access 2022

 

Video

Association for Accessible Medicines

202.249.7100

Sign-up for Updates

Receive relevant industry news, event information and the latest resources on biosimilars and generic medicines.

Stay Connected

For the latest updates, follow us on social media.